(firstQuint)Safety and Tolerability of Repatha in Indian Subjects With Homozygous Familial Hypercholesterolemia.

 An open-label, multicentre, phase 4 study to describe the safety and tolerability of Repatha in 30 Indian subjects with HoFH.

 Subjects who meet the inclusion/exclusion criteria and laboratory assessments at screening will be enrolled and will be required to maintain their current lipid-lowering drug therapy throughout the duration of the trial.

 Subjects will receive Repatha 420 mg QM SC and study visits will occur approximately every 4 weeks.

 Apheresis subjects will receive Repatha 420 mg SC every 2 weeks to correspond with their apheresis schedule.

 Final administration of Repatha (for all subjects) will occur at week 8.

 The end of study (EOS) visit will occur at week 12 for all subjects.

.

 Safety and Tolerability of Repatha in Indian Subjects With Homozygous Familial Hypercholesterolemia@highlight

To describe the safety and tolerability of Repatha in subjects with homozygous familial hypercholesterolemia (HoFH) in India.

 All subjects will receive Repatha over an 8 week period.

